Log in

NASDAQ:ALLKAllakos Stock Price, Forecast & News

$66.90
-0.39 (-0.58 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$66.01
Now: $66.90
$69.33
50-Day Range
$62.75
MA: $71.68
$80.69
52-Week Range
$30.32
Now: $66.90
$139.99
Volume164,248 shs
Average Volume353,928 shs
Market Capitalization$3.26 billion
P/E RatioN/A
Dividend YieldN/A
Beta1
Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Read More
Allakos logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALLK
CUSIPN/A
CIKN/A
Phone650-597-5002

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$10.19 per share

Profitability

Net Income$-85,370,000.00

Miscellaneous

Employees62
Market Cap$3.26 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive ALLK News and Ratings via Email

Sign-up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter.

Allakos (NASDAQ:ALLK) Frequently Asked Questions

How has Allakos' stock been impacted by COVID-19 (Coronavirus)?

Allakos' stock was trading at $58.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ALLK shares have increased by 14.8% and is now trading at $66.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Allakos?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Allakos.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Allakos.

How were Allakos' earnings last quarter?

Allakos Inc (NASDAQ:ALLK) issued its earnings results on Monday, May, 11th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.01. View Allakos' earnings history.

What price target have analysts set for ALLK?

3 analysts have issued 1-year target prices for Allakos' stock. Their forecasts range from $36.00 to $94.00. On average, they anticipate Allakos' share price to reach $65.00 in the next twelve months. This suggests that the stock has a possible downside of 2.8%. View analysts' price targets for Allakos.

Has Allakos been receiving favorable news coverage?

News coverage about ALLK stock has trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Allakos earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days. View the latest news about Allakos.

Are investors shorting Allakos?

Allakos saw a drop in short interest in June. As of June 15th, there was short interest totaling 6,820,000 shares, a drop of 7.3% from the May 31st total of 7,360,000 shares. Based on an average trading volume of 354,600 shares, the short-interest ratio is presently 19.2 days. Approximately 27.3% of the shares of the company are short sold. View Allakos' Current Options Chain.

Who are some of Allakos' key competitors?

What other stocks do shareholders of Allakos own?

Who are Allakos' key executives?

Allakos' management team includes the following people:
  • Dr. Robert Alexander, Pres, CEO & Director (Age 49)
  • Dr. Adam L. Tomasi, CFO, COO & Sec. (Age 49)
  • Dr. Henrik Sandvad Rasmussen, Chief Medical Officer (Age 60)
  • Dr. Ruby Casareno Ph.D., VP of Technical Operations
  • Mr. Mark Asbury, Chief Legal Officer & Gen. Counsel (Age 56)

When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $66.90.

How big of a company is Allakos?

Allakos has a market capitalization of $3.26 billion. The company earns $-85,370,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. Allakos employs 62 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.